Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

159.38 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 159.38
Bid (Size) 155.10 (1)
Ask (Size) 172.00 (2)
Prev. Close 159.38
Today's Range 159.38 - 159.38
52wk Range 126.97 - 225.23
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for... 
Via Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi... 
Via Talk Markets

Performance

YTD
-9.95%
-9.95%
1 Month
-8.57%
-8.57%
3 Month
-5.41%
-5.41%
6 Month
-12.65%
-12.65%
1 Year
-16.80%
-16.80%

More News

Read More
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
From BeiGene, Ltd.
Via Business Wire
Evaluating BeiGene: Insights From 6 Financial Analysts
Via Benzinga
4 Analysts Assess BeiGene: What You Need To Know
Via Benzinga
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in 3/13 Morning Trading
Via Investor Brand Network
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
7 Large-Cap Stocks That Can Jump 50% By 2025
Via InvestorPlace
Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?
Via Benzinga
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Via Talk Markets
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
From BeiGene, Ltd.
Via Business Wire
BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
Via Benzinga
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
From BeiGene, Ltd.
Via Business Wire
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
Via Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Via Talk Markets
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
Via Benzinga
Exposures Product Safety
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
From BeiGene, Ltd.
Via Business Wire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.